MC

Mary Cosgrove

Senior Manager Regulatory Affairs at C2 PHARMA

Mary Cosgrove is a highly experienced professional in the field of regulatory affairs and quality control within the pharmaceutical industry. Currently serving as a Clinical Regulatory Scientist at Eli Lilly and Company and a Senior Manager of Regulatory Affairs at C2 PHARMA, Mary has a proven track record that includes roles such as QC Expert and QC Trainer at Novartis, where responsibilities encompassed managing product transfers, optimizing training curricula, and providing analytical support for quality control activities. With extensive expertise in analytical development and quality management, Mary holds advanced degrees in Biotechnology and Biochemistry, along with various professional certifications in quality management and supervisory skills.

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


C2 PHARMA

C2 PHARMA (http://www.c2pharma.com) is a pharmaceutical group established in 2014. It manufactures and distributes active pharmaceutical ingredients (APls) and complex chemical compounds obtained from natural and synthetic origins. The current API product portfolio includes cyclopentolate, atropine, digoxin, homatropine, pilocarpine, brimonidine, latanoprost, bimatoprost and reaches more than 100 pharmaceutical companies across the United States, Western and Eastern Europe, South America, Asia, Middle-East and Africa. C² PHARMA also offers customized cold-chain logistics solutions through its specialized affiliate Logistics4Pharma  (http://www.logistics4pharma.com) as well as R&D-scale synthesis services of complex organic molecules and impurities through its affiliate ASM Research Chemicals (http://www.asm-research-chemicals.de). C² PHARMA is a key sponsor of the “Partnership for a Better World” program that ensures a sustainable, traceable & fair-trade harvesting and sourcing of phytochemical and botanicals used for pharmaceutical APIs such as Pilocarpine. The program sustains of more than 1,000 families and contributes to the preservation of the Brazilian biodiversity. #c2Pharma; #C²Pharma; #c2 Pharma; #C² Pharma; #Centroflora CMS